Advertisement

Drugs

, Volume 79, Issue 15, pp 1709–1718 | Cite as

Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson’s Disease

  • Sheridan M. HoyEmail author
Adis Drug Evaluation
  • 121 Downloads

Abstract

An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including those of the EU (under the Mutual Recognition Procedure), it is approved for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. In several other countries, including the USA, it is approved for the treatment of motor fluctuations in patients with advanced PD. In adults with advanced PD, levodopa/carbidopa ES improved motor fluctuations, activities of daily living and health-related quality of life (HR-QOL) during short-term (12-week) treatment, with the beneficial effects on motor fluctuations largely sustained over the longer term (up to 7 years). Levodopa/carbidopa ES was generally well tolerated in this patient population, with adverse events (AEs) associated with aging, advanced PD-related comorbidities, the procedure/device or dopaminergic therapy. Its safety profile was comparable to that of oral levodopa/carbidopa with respect to non-procedure/device-associated AEs; most procedure/device-associated AEs were consistent in nature and incidence with medically recognised complications of the procedure in non-PD patients. Current evidence indicates that levodopa/carbidopa ES is an effective and generally well tolerated option for the treatment of motor fluctuations in patients with levodopa-responsive advanced PD who are not being effectively managed with non-invasive therapies.

Notes

Acknowledgements

During the peer review process, the manufacturer of levodopa/carbidopa enteral suspension was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Pedersen SW, Clausen J, Gregerslund MM. Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic. Open Neurol J. 2012;6(1):37–50.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.PubMedCrossRefGoogle Scholar
  3. 3.
    Freitas ME, Ruiz-Lopez M, Fox SH. Novel levodopa formulations for Parkinson’s disease. CNS Drugs. 2016;30(11):1079–95.PubMedCrossRefGoogle Scholar
  4. 4.
    Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.PubMedCrossRefGoogle Scholar
  5. 5.
    Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Greig SL, McKeage K. Carbidopa/levodopa ER capsules (Rytary((R)), Numient): a review in Parkinson’s disease. CNS Drugs. 2016;30(1):79–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Greig SL. Carbidopa/levodopa enteral suspension in advanced Parkinson’s disease: a guide to its use. Drugs Ther Perspect. 2016;32(5):177–85.CrossRefGoogle Scholar
  8. 8.
    Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Murata M, Mihara M, Hasegawa K, et al. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients. NPJ Parkinsons Dis. 2016;2:16020.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    AbbVie Ltd. Duodopa 20 mg/mL + 5 mg/mL intestinal gel: UK summary of product characteristics. 2017. http://www.medicines.org.uk/emc/. Accessed 12 Dec 2018.
  11. 11.
    Slevin JT, Fernandez HH, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis. 2015;5(1):165–74.PubMedGoogle Scholar
  12. 12.
    Murata M, Mihara M, Hasegawa K, et al. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease. Ther Adv Neurol Disord. 2018.  https://doi.org/10.1177/1756286418759315.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Fernandez HH, Boyd JT, Fung VSC, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease. Mov Disord. 2018;33(6):928–36.PubMedCrossRefGoogle Scholar
  14. 14.
    Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Valldeoriola F, Grandas F, Santos-Garcia D, et al. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson’s disease. Neurodegener Dis Manag. 2016;6(4):289–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Lopiano L, Modugno N, Marano P, et al. Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol. 2019;266(9):2164–76.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease. Eur J Neurol. 2012;19(8):1079–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Tessitore A, Marano P, Modugno N, et al. Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study. J Neurol. 2018;265(5):1124–37.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Palhagen SE, Sydow O, Johansson A, et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord. 2016;29:17–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Kruger R, Lingor P, Doskas T, et al. An observational study of the effect of levodopa-carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson’s disease patients. Adv Ther. 2017;34(7):1741–52.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Antonini A, Fung VS, Boyd JT, et al. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov Disord. 2016;31(4):530–7.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Poewe W, Bergmann L, Kukreja P, et al. Levodopa-carbidopa intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety. J Parkinsons Dis. 2019;9(3):531–41.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31(4):538–46.PubMedCrossRefGoogle Scholar
  25. 25.
    European Medicines Agency. Public summary of position opinion for orphan designation of levodopa/carbidopa (gastroenteral use). 2016. http://www.ema.europa.eu/en. Accessed 22 Mar 2019.
  26. 26.
    AbbVie Inc. DUOPA (carbidopa and levodopa) enteral suspension: US prescribing information. 2018. http://www.rxabbvie.com/. Accessed 12 Dec 2018.
  27. 27.
    Lang AE, Espay AJ. Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord. 2018;33(5):660–77.PubMedCrossRefGoogle Scholar
  28. 28.
    Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–71.CrossRefGoogle Scholar
  29. 29.
    Hely MA, Morris JG, Reid WG, et al. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.CrossRefGoogle Scholar
  31. 31.
    Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–66.PubMedCrossRefGoogle Scholar
  32. 32.
    Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15.PubMedCrossRefGoogle Scholar
  34. 34.
    National Institute for Health and Care Excellence. Parkinson’s disease in adults. 2017. https://www.nice.org.uk/. Accessed 19 Jun 2019.
  35. 35.
    Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Obeso JA, Olanow CW, Rodriguez-Oroz MC, et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med. 2001;345(13):956–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78(1):94–105.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Amjad F, Bhatti D, Davis TL, et al. Current practices for outpatient initiation of levodopa-carbidopa intestinal gel for management of advanced Parkinson’s disease in the United States. Adv Ther. 2019;36(9):2233–46.PubMedCrossRefGoogle Scholar
  39. 39.
    Lew MF, Slevin JT, Kruger R, et al. Initiation and dose optimization for levodopa-carbidopa intestinal gel: insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015;21(7):742–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Martinez-Martin P, Rodriguez-Blazquez C, Paz S, et al. Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis. PLoS ONE. 2015;10(12):e0145310.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Kalabina S, Belsey J, Pivonka D, et al. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales. J Med Econ. 2019;22(3):215–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Lowin J, Sail K, Baj R, et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ. 2017;20(11):1207–15.PubMedCrossRefGoogle Scholar
  43. 43.
    Politis M, Sauerbier A, Loane C, et al. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson’s disease patients. Mov Disord. 2017;32(2):235–40.PubMedCrossRefGoogle Scholar
  44. 44.
    Nyholm D, Odin P, Johansson A, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J. 2013;15(2):316–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Othman AA, Rosebraugh M, Chatamra K, et al. Levodopa-carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa-carbidopa. J Parkinsons Dis. 2017;7(2):275–8.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Othman AA, Chatamra K, Mohamed ME, et al. Jejunal infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in Japanese subjects with advanced Parkinson’s disease: pharmacokinetics and pilot efficacy and safety. Clin Pharmacokinet. 2015;54(9):975–84.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord. 2011;26(5):813–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations